Switch theme
Sign up to access all valuation multiples
EXoZymes Inc is focused on using a biomanufacturing platform to create valuable biochemicals, including Active Pharmaceutical Ingredients or APIs, biofuels, food flavors, and cosmetics, offering a sustainable alternative to traditional chemical production methods.
2019
31
Last FY Revenue n/a
Last FY EBITDA -$5.7M
$105M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, eXoZymes achieved revenue of n/a and an EBITDA of -$5.7M.
eXoZymes expects next 12-month revenue of XXX and NTM EBITDA of XXX
See eXoZymes valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$5.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | n/a | XXX | XXX | XXX |
| EBIT | XXX | -$5.9M | XXX | XXX | XXX |
| EBIT Margin | XXX | n/a | XXX | XXX | XXX |
| Net Profit | XXX | -$5.9M | XXX | XXX | XXX |
| Net Margin | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, eXoZymes's stock price is $13.
eXoZymes has current market cap of $112M, and EV of $105M.
See eXoZymes trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $105M | $112M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, eXoZymes has market cap of $112M and EV of $105M.
eXoZymes's trades at n/a EV/Revenue multiple, and -18.5x EV/EBITDA.
Equity research analysts estimate eXoZymes's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
eXoZymes's P/E ratio is not available.
See valuation multiples for eXoZymes and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $112M | XXX | $112M | XXX | XXX | XXX |
| EV (current) | $105M | XXX | $105M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -18.5x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -17.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -19.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -11.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialeXoZymes's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.2M for the same period.
eXoZymes's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
eXoZymes's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for eXoZymes and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Borouge | XXX | XXX | XXX | XXX | XXX | XXX |
| Fertiglobe | XXX | XXX | XXX | XXX | XXX | XXX |
| Akzo Nobel | XXX | XXX | XXX | XXX | XXX | XXX |
| Avantium | XXX | XXX | XXX | XXX | XXX | XXX |
| DSM Firmenich | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
eXoZymes acquired XXX companies to date.
Last acquisition by eXoZymes was XXXXXXXX, XXXXX XXXXX XXXXXX . eXoZymes acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was eXoZymes founded? | eXoZymes was founded in 2019. |
| Where is eXoZymes headquartered? | eXoZymes is headquartered in United States of America. |
| How many employees does eXoZymes have? | As of today, eXoZymes has 31 employees. |
| Who is the CEO of eXoZymes? | eXoZymes's CEO is Mr. Michael Heltzen. |
| Is eXoZymes publicy listed? | Yes, eXoZymes is a public company listed on NAS. |
| What is the stock symbol of eXoZymes? | eXoZymes trades under EXOZ ticker. |
| When did eXoZymes go public? | eXoZymes went public in 2024. |
| Who are competitors of eXoZymes? | Similar companies to eXoZymes include e.g. Borouge, Fertiglobe, Akzo Nobel, Avantium. |
| What is the current market cap of eXoZymes? | eXoZymes's current market cap is $112M |
| Is eXoZymes profitable? | Yes, eXoZymes is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
